Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
March 19, 2024
Beyond early detection, how do we bridge the gap in metastatic colorectal cancer care. Learn about Takeda’s partnerships for patient support.
If you are a journalist or member of the media looking for Takeda Oncology resources, visit the media materials section of our newsroom.
For other Takeda news releases, please visit the Takeda.com Newsroom.
For media inquiries or reporter requests for more information, contact Oncology Communications via [email protected]. If you generally would like to contact us, please visit Contact Us.